A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to ...

AstraZeneca scrapped plans for a £450 million UK vaccine plant after rejecting a £78 million government offer, citing ...

AstraZeneca share rose after it that the company has secured permission to import pharmaceutical formulations of new drug for sale or for distribution in Form CT-20 from CDSCO ...

If you purchased or acquired securities in AstraZeneca between between February 23, 2022 and December 17, 2024 and would like ...

Only around five months ago, AstraZeneca’s (LSE: AZN) share price hit a point that made the firm the UK’s first £200bn listing. Now, it is down 20% from its 3 September 12-month traded high of £133.38 ...

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Astrazeneca (AZN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the ...

Britain on Monday hit back at AstraZeneca over the collapse of a 450 million pound ($558.5 million) investment, saying the drugmaker had scaled back the research and development portion of its plans, ...

The user of the website is referred to as "you" and "your". By posting on our share chat boards you are agreeing to the following: If you are going to post non-English, please also post an English ...

AstraZeneca on Friday scrapped plans to invest 450 million pounds ($558.3 million) in its vaccine manufacturing plant in ...

AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.

(Alliance News) - AstraZeneca PLC on Monday said Imfinzi has been recommended for approval in the EU as monotherapy for limited-stage small cell lung cancer.

AstraZeneca’s share price has fallen a long way from its record-breaking level last year, which indicates that I may be getting a huge bargain. When investing, your capital is at risk.